Counterfeit Ozempic Lot Numbers: 30 Identifiers in Official Alerts, 2023–2026

Weight Loss Provider Guide Editorial Team
Last verified: August 3, 2026 · Dataset version 1.0.2 · Dataset ID wpg-counterfeit-ozempic-identifiers-2026-08-03

As of August 3, 2026, we found 30 unique exact Ozempic lot, batch, or serial-qualified identifier strings named in publicly accessible official notices located under the method on this page. Twenty-one appear in confirmed, regulator-reported, or actively investigated counterfeit configurations. Six are suspected only. Three are authentic Colombia-market lots flagged in Mexico for a completely different reason — they were being sold in a country where they were not authorized, which is not the same thing as being fake.

All 30 records concern injectable or pre-filled-pen presentations described in the reviewed notices.

Here is the part almost every list gets wrong:

A matching lot number does not, by itself, prove an Ozempic pen is counterfeit. And a lot number absent from this register does not prove a pen is authentic.

That is not a hedge. It is what the regulators themselves say. FDA states that PAR1229 “also is an authentic lot number.” WHO says batch MP5E511 is genuine even though the product was falsified. Anvisa says NP5K174 is an original authentic Ozempic lot whose labels may have been removed and reused on Fiasp insulin pens in a fraud that was still under investigation.

So the useful question is not “is my lot number on a list?” It is “does my product match the full condition the alert describes?” That condition may be a serial number, a label layout, a market, an expiry date, a pen design, or a mismatch between the carton and the pen inside it.

Source: Weight Loss Provider Guide Research, Counterfeit Ozempic Lot Numbers Register v1.0.2, compiled from the row-level official sources shown below. Verified August 3, 2026.

Counterfeit Ozempic lot numbers in U.S. FDA alerts

Answer capsule: FDA’s public page contains three U.S. counterfeit configurations: NAR0074 with one exact serial, PAR0362 with a serial prefix, and PAR1229 with a label-position rule. Zero of the three can be interpreted safely from the lot number alone.

If you are in the United States, this is the fastest answer. All three entries appear on one FDA alert page, under updates dated December 21, 2023; April 14, 2025; and December 5, 2025.

Source: U.S. Food and Drug Administration, counterfeit Ozempic alert; authenticity of PAR0362 also confirmed in Novo Nordisk’s April 14, 2025 statement. Sources reopened and verified August 3, 2026.

Notice the progression. In December 2023 the alert required two printed numbers. In April 2025 the lot still was not enough — the serial prefix mattered. By December 2025 the lot was shared by authentic and counterfeit product, and FDA’s published distinction was where the EXP/LOT text sits on the label.

If you are worried right now: if your product matches the full counterfeit condition in an alert, or you have another reason to suspect it is counterfeit, do not use it until it has been checked. Keep the carton and pen if you safely can, contact the dispensing pharmacy, and follow the regulator’s or manufacturer’s instructions. In the United States, FDA lists Novo Nordisk Customer Care at 1-800-727-6500, Monday through Friday, 8:30 a.m. to 6 p.m. Eastern. If you used a suspect product and feel unwell, seek medical care. TGA advises emergency help for severe low-blood-sugar symptoms after use of a suspect Ozempic-labeled product.

What does the counterfeit Ozempic lot number data show — and what does it not show?

Answer capsule: The register shows which exact strings authorities publicly named and the condition attached to each. It does not count counterfeit units, estimate prevalence, authenticate an individual pen, or establish that an unlisted product is genuine.

Three limits matter before you read the full tables.

It measures public notices, not prevalence. Thirty is a count of unique exact strings we located in publicly accessible official records through August 3, 2026. It is not a count of products, seizures, patients, countries affected, or counterfeit units in circulation.

Thirty is not the universe of legitimate Ozempic lots. The absence of a lot number means only that it was not located in the public alert universe defined by this method. It does not clear a product.

Some public records are thin. A regulator-to-regulator bulletin may name an identifier without publishing the photographs, serials, laboratory results, or product description needed to recognize an individual pack. Those rows remain in the register, but they are labeled as having limited public detail.

How was the counterfeit Ozempic identifier register built?

Answer capsule: We used publicly accessible official records, transcribed each identifier exactly as printed, applied the strongest status the source actually supports, and deduplicated by exact string while retaining every incident and source. The 30-row count is reproducible from the downloadable CSV and JSON files.

Source universe. WHO alerts; national medicines-regulator safety alerts; government decisions and recall notices; official regulator-to-regulator bulletins; EMA records; and original manufacturer records used only for manufacturer-established facts such as whether a lot number is authentic.

Inclusion rule. An exact Ozempic lot, batch, serial-qualified batch, or printed batch identifier explicitly named in an official counterfeit, falsification, suspected-falsification, recall, or market-irregularity notice.

Exclusion rule. Media-only identifiers, private investigative material, generic warnings without an identifier, and ambiguous strings we could not confirm in an accessible official record.

Deduplication rule. Exact identifier string. A string named by five authorities counts once toward the total of 30, while all five incidents remain attached to the row.

Transcription rule. We preserve the source string exactly. We do not silently turn a zero into a letter O, a 5 into an 8, or unusual punctuation into something more familiar.

Conservative rule. “Possible,” “suspected,” and “under investigation” remain possible, suspected, and under investigation unless a later official record supports a stronger status. That rule keeps MP5D558 in Group B.

Status-change rule. A later alert adds to the history instead of erasing the earlier fact. PP5K617 was described in 2025 as an authentic Colombia-market lot not authorized in Mexico, then appeared in a 2026 counterfeit-presentation alert. Both facts stay.

Restricted-source rule. A regulator-restricted surveillance request that was publicly hosted but labeled not for public circulation was removed from the source universe during the production audit. Details found only there — including displayed expiries previously attached to MP5A370 and MP5D600 — do not appear in version 1.0.2.

What we excluded, and why

Publishing a string that turns out to be a transcription artifact would be worse than publishing nothing. Candidate strings found only in private or non-public material, unverified secondary or mirrored references, or ambiguous variants that could not be confirmed in an accessible official record were excluded and remain in the internal claim ledger. They are not counted in the 30-row public dataset.

Which 21 identifiers appear in confirmed, regulator-reported, or investigated counterfeit configurations?

Answer capsule: Group A contains 21 exact strings attached to an affirmative official counterfeit, falsification, non-genuine-product, or active relabeling investigation record. The group describes configurations, not a claim that every authentic product bearing one of those strings is counterfeit.

The word configuration is doing real work. When a genuine lot is copied, the counterfeit thing is the product — its serial, label, pen, carton, contents, or market history — not the lot number in the abstract.

Source: Each row links to the issuing regulator, WHO, or original manufacturer record. Dataset compilation and exact-string deduplication: Weight Loss Provider Guide Research, v1.0.2, verified August 3, 2026.

Which six Ozempic identifiers are suspected only?

Answer capsule: Six exact strings remain suspected or precautionary rather than publicly confirmed. They are separated so a regulator’s suspicion does not become a statement of fact when the data is copied or summarized.

Sources: Egyptian Drug Authority awareness letter; EDA package-comparison sheet; Malta Medicines Authority recall; and SÚKL’s July 26, 2024 Thai-authority relay. Verified August 3, 2026.

Two details matter more than they look.

PP5N682::RN287 is one printed batch identifier. The double colon is how the Maltese authority reported it. Shortening it to PP5N682 changes the scope of the recall.

The near-identical strings are real, but the exact count matters. Two suspected strings — MP58060 and MP4B060 — are each one character away from confirmed MP5B060. MP58058 is two characters away from MP58060, not one. A person comparing tiny carton print against a phone screen can still match the wrong string in either direction, but the dataset should not exaggerate the similarity.

Which three Ozempic lots were authentic but unauthorized in Mexico?

Answer capsule: COFEPRIS described three lots as authentic product intended for Colombia but not authorized for commercialization in Mexico. That is a traceability and market-authorization problem, not evidence that the medicine was falsified.

Source: COFEPRIS, Ozempic falsification and irregular-commercialization alert, June 17, 2025. Verified August 3, 2026.

These three appeared in the same alert as PP7K381, which COFEPRIS said did not exist in company records. A flat “lots named by COFEPRIS” list would put authentic and nonexistent identifiers in the same bucket. We do not.

Which authentic Ozempic lot numbers have appeared on counterfeit-related products?

Answer capsule: At least five of the 30 identifiers — 16.7% — are explicitly described as authentic in a specific batch or market context while also appearing in a counterfeit-related record. That one-in-six finding is why a lot-only blacklist is not an authentication test.

Sources: WHO; FDA; Novo Nordisk; Anvisa; and COFEPRIS. Original five-row comparison: Weight Loss Provider Guide Research, verified August 3, 2026.

The 2023 European incident shows the structural problem. EMA reported that falsified packs carried batch numbers, 2D barcodes, and unique serial numbers taken from genuine Ozempic packs. When the packs were scanned in the European verification system, the serial numbers appeared inactive. The printed strings had been copied; the verification-system status exposed the problem.

The safe conclusion is narrower than the original draft’s absolute version:

A printed identifier can be copied. In the 2023 EU incident, the copied serials were detected because their database status was inactive when scanned.

The reviewed FDA materials do not provide a public patient serial-number lookup for Ozempic. Under the Drug Supply Chain Security Act, verification requests and suspect-product investigations run through authorized trading partners such as manufacturers, wholesalers, and dispensers. That is why the dispensing pharmacy is part of the practical answer.

Does a matching Ozempic lot number prove the pen is fake?

Answer capsule: No. A listed string may appear on authentic medicine, while an unlisted string may belong to a counterfeit product that has not been publicly catalogued. A lot-number lookup is a screening step, not a verdict.

False alarm. At least five authentic identifiers appear somewhere in this register. Matching one of them without applying the serial, label, market, device, or relabeling condition can misclassify authentic medicine.

False reassurance. An absent identifier does not clear a product. The register captures public notices, and public notices are not the same thing as every detection or investigation.

WHO’s public June 2024 Ozempic alert covers three falsified batches. FDA’s U.S. page covers three U.S. configurations. TGA covers its Australian detections. COFEPRIS covers Mexican alerts. No single official global identifier register was located in this audit, which is why the source assembly exists — but this page still cannot turn absence into proof.

What actually distinguishes a counterfeit Ozempic pen?

Answer capsule: The reviewed alerts use at least seven recurring evidence types: exact serials, serial prefixes, label placement, carton/pen mismatches, wrong devices or colors, typography or build differences, and supply-chain database status. None gives an ordinary reader a universal visual authentication method.

Sources: FDA; WHO; EMA; TGA 2024; TGA 2025; Anvisa; COFEPRIS March 2026; and COFEPRIS May 2026. Original cross-alert feature taxonomy: Weight Loss Provider Guide Research, verified August 3, 2026.

The carton and the pen can disagree. COFEPRIS’s March 26, 2026 alert described a carton labeled JS7A925, expiry 06/2026, holding a pen labeled MP5E511, expiry 07/2025. The authority reported that the configuration did not contain the active ingredient.

The pen can be the wrong device. COFEPRIS’s May 25, 2026 alert identified a PP5K617 presentation whose pen differed from the genuine FlexTouch device.

Color can expose a relabeling incident. Anvisa’s guidance says Ozempic pens are light blue with a gray injection button, while Fiasp pens are dark blue with an orange button. That comparison belongs to the investigated Fiasp relabeling pattern; it is not a universal global authentication checklist.

Typography may be the only published visual clue. TGA reported spacing and bolding differences for MPSD916. FDA’s published distinction for PAR1229 is the position of EXP/LOT text. When the difference is letter placement, an untrained eye is not a dependable final authority.

How do you check an Ozempic lot number and serial number?

Answer capsule: For the pen products covered here, compare the carton and pen first, then apply the exact condition in the official notice for the market where the medicine was dispensed. Final authentication belongs to the dispensing pharmacy, regulator, or manufacturer — not to a photo or this lookup.

1. Read both the carton and the pen. Record the lot, serial where present, expiry, language, and dose. A carton/pen lot or expiry mismatch is a documented signal.
2. Use the complete rule. For NAR0074 and PAR0362, the serial condition matters. For PAR1229, label placement matters. For PP5K617, both market history and pen type matter.
3. Check the market. Spanish or Portuguese packaging is not automatically fake in a market where that presentation is authorized. A genuine product can become an unauthorized-market product after crossing a border.
4. Contact the dispensing pharmacy. In the United States, pharmacies and other authorized trading partners can initiate or coordinate product-identifier verification and suspect-product investigation under the DSCSA framework.
5. Contact the regulator or manufacturer when needed. FDA and Novo Nordisk direct U.S. questions about the named products to Novo Nordisk Customer Care at 1-800-727-6500 during the hours listed on the FDA alert.

You cannot authenticate medicine from a photograph alone. You also cannot conclude that a product is genuine because a call center in one country cannot find a lot intended for another market.

What should you do if your Ozempic matches an alert?

Answer capsule: First decide whether it matches the full counterfeit condition, not merely a shared lot number. If it does — or if you otherwise suspect counterfeiting — do not use it until the dispensing pharmacy, regulator, or manufacturer has checked it.

1. Stop before the next dose. Do not inject, distribute, or sell a product that matches the full counterfeit condition or is otherwise suspected to be counterfeit.
2. Keep the evidence when safe. Preserve the carton, pen, inserts, receipt, dispensing label, photographs, lot, serial, and expiry until you receive handling instructions. TGA asks people not to dispose of suspected product because it may be requested for testing.
3. Call the dispensing pharmacy. The pharmacy has the transaction record and access to the professional supply-chain verification route.
4. Report the right problem. In the United States, report adverse events and product-quality problems through FDA MedWatch. Report suspected criminal counterfeit activity through FDA’s Office of Criminal Investigations route. Outside the United States, use the national medicines regulator’s reporting channel.
5. Get urgent help for severe symptoms. TGA lists weakness, trembling, shaking, confusion, and unconsciousness among severe low-blood-sugar warning signs after use of a suspect Ozempic-labeled product. Call emergency services for severe symptoms.

This page is educational. It cannot authenticate your medicine and it is not a substitute for advice from a pharmacist, prescriber, manufacturer, or regulator.

What was found inside counterfeit Ozempic products?

Answer capsule: The contents and components differed by incident. Official findings include insulin glulisine, no active ingredient, counterfeit needles and packaging, and products whose composition remained unpublished or under testing.

Sources: TGA 2024; DIGEMID 81; COFEPRIS March 2026; and FDA. Verified August 3, 2026.

The phrase “fake Ozempic contains insulin” is therefore too broad. Some tested products did. Another official configuration reportedly contained no active ingredient. For several records, the public source did not establish the contents at all.

FDA’s adverse-event wording also needs to remain exact. Its April and December 2025 updates each discussed six reports associated with the named lot but said none appeared linked to the counterfeit product; the December update said the six reports were associated with authentic Ozempic. Its 2023 update described five non-serious reports consistent with known reactions to authentic Ozempic.

Why does this counterfeit Ozempic data matter now?

Answer capsule: Counterfeit Ozempic has appeared in regulated or legitimate supply chains, and the published matching rules now include details too specific for a flat lot-number list. The useful asset is the condition-aware record, not a blacklist stripped of serials, labels, markets, and status.

Supply route is not a complete safeguard. WHO said the three batches in its 2024 alert were supplied in the regulated supply chain. FDA said the products in its U.S. alerts were distributed outside Novo Nordisk’s authorized supply chain but entered the legitimate U.S. drug supply chain.

The three U.S. conditions are all context-dependent. One requires an exact serial, one requires a serial prefix, and one requires label placement. That is an original three-record comparison, and it is why the U.S. table sits near the top of this page.

The global evidence is fragmented. The 30-row register draws from more than a dozen public official records across agencies and languages. No single authority page contains the 21/6/3 split, the five authentic-but-counterfeit-related identifiers, or the exact-string comparison in Group B.

Download the underlying data

Answer capsule: The full 30-row register, machine-readable JSON, and source register are available as versioned files without registration. Each file has a published SHA-256 hash so the exact edition can be identified later.

• Identifier register v1.0.2, CSV
• Identifier register v1.0.2, JSON
• Primary-source register v1.0.2, CSV

File hashes

524186df5e463b8280bd5bf990fb3ddc0d4e4d6e564c697c8b60d8200d768257  wpg-counterfeit-ozempic-identifiers-v1.0.2.csv
83ee9438ee2ea66328fea837eea8644d0d9cdf375cb4ce9e81bbb0b59453e8cb  wpg-counterfeit-ozempic-identifiers-v1.0.2.json
b26997361d6311fdc987ddba6af594bf12712b0078519291890609f0480730f6  wpg-counterfeit-ozempic-sources-v1.0.2.csv

Version history

Source: Weight Loss Provider Guide Research version control. A verification date changes only when the underlying source review has been rerun.

What are the limitations of this register?

Answer capsule: This is a transparent public-alert register, not a global prevalence study or an individual authentication service. Its most important limitation is the same as its main finding: a string can be real, copied, suspected, market-limited, or meaningful only with another condition.

We would rather state the limits plainly than have someone rely on the page for more than it can carry.

• The register is not exhaustive of every counterfeit Ozempic product or confidential investigation.
• Official publication can lag detection, and counterfeiters can introduce new identifiers.
• The register measures publicly named exact strings, not counterfeit unit volume or prevalence.
• A listed identifier may require an exact serial, label feature, market, expiry, device, or carton/pen combination before it supports a conclusion.
• An unlisted identifier does not prove authenticity.
• Multiple incidents can share one identifier, and different products using the same identifier can contain different substances.
• Some rows rest on regulator-to-regulator bulletins that name a string without publishing enough detail to recognize a pack.
• “Falsified,” “counterfeit,” “suspected,” “under investigation,” and “irregular commercialization” are not interchangeable. The register preserves those distinctions.
• Several sources are not in English. Identifier strings are retained exactly as printed.
• Market authorization in one country does not automatically apply in another.
• Historical identifiers remain in the register after their printed expiry because expired stock and past investigations do not disappear from the research record.
• All 30 records concern injectable or pen presentations in the reviewed notices. This dataset should not be treated as a register for other dosage forms.

Frequently asked questions

Answer capsule: These answers cover the highest-risk follow-ups: where to find the identifiers, what a match means, why authentic lots can appear in counterfeit records, and what to do with a suspect product. Every answer uses the same condition-based rule as the register.

Where is the lot number on an Ozempic pen?

For the pre-filled pens covered by these alerts, check the outside of the carton and the label wrapped around the pen. Compare both the lot number and the expiry date; a carton/pen mismatch is the exact condition COFEPRIS described in March 2026.

Can a real Ozempic lot number appear on a fake pen?

Yes. WHO states that MP5E511 is a genuine batch number even though the product was falsified. PAR0362, PAR1229, NP5K174 and PP5K617 are also described as authentic in a specific context while appearing in counterfeit-related records.

Is PAR0362 counterfeit?

PAR0362 is an authentic lot number. The U.S. counterfeit condition is PAR0362 combined with a serial number beginning with the first eight digits 51746517; the lot by itself does not establish counterfeit status.

Is PAR1229 counterfeit?

PAR1229 is also an authentic lot number. FDA distinguishes the counterfeit pen by EXP/LOT text positioned to the left of the expiration date and lot number; on the authentic pen it appears above them.

Is NAR0074 counterfeit?

The FDA and WHO alert condition is the combination of lot NAR0074 and serial number 430834149057. The safe matching unit is the lot and serial together, not the lot alone.

What if my Ozempic lot number is not listed here?

That does not establish authenticity. This register covers exact strings that authorities publicly named under the stated method; a new, unreported or confidentially investigated counterfeit can use a different identifier.

Can counterfeit Ozempic contain insulin?

Yes, in some confirmed incidents. TGA laboratory testing found insulin glulisine in two counterfeit Ozempic-labeled pens, and the MP5B060 notice described another tested relabeled sample containing insulin glulisine. Other counterfeit configurations had different or unknown contents.

Can counterfeit Ozempic contain no semaglutide?

Yes. COFEPRIS reported that the March 2026 configuration with carton lot JS7A925 and pen lot MP5E511 did not contain the active ingredient.

Does foreign-language packaging mean Ozempic is fake?

No. Packaging language reflects the market for which a product was made. Three identifiers in this register are authentic Colombia-market lots named by Mexico because they were not authorized there, not because the products were proven falsified.

Should I throw away suspected counterfeit Ozempic?

Do not use a product that matches the full counterfeit condition or that you otherwise suspect is counterfeit. Keep the product and packaging if it is safe to do so until the dispensing pharmacy, regulator or manufacturer tells you how to handle it, because an authority may request the product for testing.

How to cite this page

Answer capsule: The block below supplies neutral bibliographic information for this edition of the page and dataset.

Weight Loss Provider Guide Editorial Team. “Counterfeit Ozempic Lot Numbers:
30 Identifiers in Official Alerts, 2023–2026.” Weight Loss Provider Guide Research.
Dataset version 1.0.2. Last verified August 3, 2026.
https://weightlossproviderguide.com/research/counterfeit-ozempic-lot-numbers/

Who produced this register, and why?

Answer capsule: Weight Loss Provider Guide Editorial Team produced the register through manual extraction, exact-string transcription, conservative classification, deduplication, and row-level source mapping. It exists because a flat list of “bad lots” can label authentic medicine as fake and strip away the condition that makes an alert meaningful.

Weight Loss Provider Guide Research is the independent, self-funded research and reference section of Weight Loss Provider Guide. This research page contains no affiliate links, advertising, product or provider recommendations, lead routing, email capture, or commercial call to action.

Where a record says only “suspected,” this page says suspected. Where an authentic lot was copied, this page names the counterfeit configuration instead of branding the whole lot fake. Where a regulator relay provides thin detail, that limitation stays visible.

The register is checked when an authority publishes a new identifier, matching condition, laboratory result, correction, or status change. The “Last verified” date changes only after the source review is rerun.

Primary sources

Answer capsule: The register relies on issuing regulators, government records, WHO, EMA, and the original manufacturer where the manufacturer established a lot’s authenticity. Secondary reporting and forum posts are not used as factual evidence.

• U.S. Food and Drug Administration — counterfeit Ozempic alert
• Novo Nordisk — April 14, 2025 PAR0362 statement
• World Health Organization — Medical Product Alert N°2/2024
• European Medicines Agency — falsified Ozempic pens, October 18, 2023
• Australia TGA — NPSG234 and JS7A925
• Australia TGA — MPSD916
• Brazil Anvisa — LP6F832
• Brazil Anvisa — NP5K174 relabeling investigation
• Colombia Invima — Alert 200-2024
• Mexico COFEPRIS — June 17, 2025
• Mexico COFEPRIS — March 26, 2026
• Mexico COFEPRIS — May 25, 2026
• Peru DIGEMID — Alert 81-2023
• Peru DIGEMID — Alert 90-2023
• Czech SÚKL — Bulletin 02/2024
• Czech SÚKL — Monthly Information 11/2024
• Czech SÚKL — Thai-authority update, July 26, 2024
• Poland Chief Pharmaceutical Inspectorate — October 12, 2023 decision
• North Macedonia MALMED — October 31, 2023 notice
• Egyptian Drug Authority — Awareness Letter No. 1 of 2024
• Egyptian Drug Authority — linked package-comparison sheet
• Malta Medicines Authority — PP5N682::RN287 recall, August 11, 2025
• UK MHRA — FOI response on falsified Ozempic packs
• FDA — consumer reporting routes for human drugs
• FDA — DSCSA verification-systems guidance

Related research

Answer capsule: These pages cover adjacent medication-safety, privacy, coverage, and spending questions without changing this page’s noncommercial purpose. The links point to specific research assets rather than a generic hub.

• Compounded Semaglutide Recalls: Complete Tracker
• GLP-1 Telehealth Privacy Audit: 12-Provider Data
• GLP-1 Insurance Coverage Mandates by State
• Medicare GLP-1 Spending by Prescriber State